Search results for " CD"

showing 10 items of 587 documents

Hemopoietic and angiogenetic progenitors in healthy athletes: different responses to endurance and maximal exercise

2010

J Appl Physiol. 2010 Jul;109(1):60-7. Epub 2010 May 6. Hemopoietic and angiogenetic progenitors in healthy athletes: different responses to endurance and maximal exercise. Bonsignore MR, Morici G, Riccioni R, Huertas A, Petrucci E, Veca M, Mariani G, Bonanno A, Chimenti L, Gioia M, Palange P, Testa U. SourceBiomedical Department, Internal and Specialistic Medicine (DIBIMIS), Section of Pneumology, University of Palermo, Via Trabucco, 180, 90146 Palermo, Italy. marisa@ibim.cnr.it Abstract The effects of endurance or maximal exercise on mobilization of bone marrow-derived hemopoietic and angiogenetic progenitors in healthy subjects are poorly defined. In 10 healthy amateur runners, we collect…

AdultMalemedicine.medical_specialtyPhysiologyNeovascularization PhysiologicAntigens CD34Physical exerciseHematopoietic Cell Growth FactorsSettore BIO/09 - FisiologiaRunningangiopoietin; marathon; circulating progenitors; growth factorsAntigens CDEndurance trainingPhysiology (medical)Internal medicinegrowth factorsmedicineHumansAC133 AntigenProgenitor cellGlycoproteinsErythroid Precursor CellsbiologyAthletesbusiness.industryangiopoietinHealthy subjectsEndothelial Cellscirculating progenitorMiddle AgedCadherinsHematopoietic Stem Cellsbiology.organism_classificationHaematopoiesisEndocrinologyAthletesPhysical EnduranceCytokinesAngiogenesis Inducing Agentsadult; angiogenesis inducing agents; angiopoietin; antigens; athletes; blood; cadherins; cd; cd34; circulating progenitors; cytokines; endothelial cells; erythroid precursor cells; glycoproteins; granulocytes; growth factors; hematopoietic cell growth factors; hematopoietic stem cells; humans; male; marathon; middle aged; neovascularization; peptides; physical endurance; physiologic; physiology; runningAC133 antigenMaximal exercisemarathonPeptidesbusinessGranulocytesJournal of Applied Physiology
researchProduct

The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis

2009

Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) inhibits T-cell activation and interleukin-2 (IL-2) production. The PTPN22(gain-of-function)+1858T(+) genotypes predispose to multiple autoimmune diseases, including early-onset (non-thymomatous) myasthenia gravis (MG). The disease association and the requirement of IL-2/IL-2 receptor signaling for intrathymic, negative T-cell selection have suggested that these genotypes may weaken T-cell receptor (TCR) signaling and impair the deletion of autoreactive T cells. Evidence for this hypothesis is missing. Thymoma-associated MG, which depends on intratumorous generation and export of mature autoreactive CD4(+) T cells, is a model of au…

AdultMalemedicine.medical_specialtyThymomaAdolescentGenotypeThymomaImmunologyBiologymedicine.disease_causePolymorphism Single NucleotideWhite PeopleAutoimmunityPTPN22Young AdultAntigens CDInternal medicineMyasthenia GravisCentral tolerance inductionGeneticsmedicineHumansCTLA-4 AntigenGenetic Predisposition to DiseaseReceptorGenetics (clinical)AgedAged 80 and overT-cell receptorProtein Tyrosine Phosphatase Non-Receptor Type 22Thymus NeoplasmsMiddle Agedmedicine.diseaseMyasthenia gravisEndocrinologyImmunologyInterleukin-2FemaleCentral toleranceGenes & Immunity
researchProduct

Comparison of intermittent- and continuous-flow cell separators for the collection of autologous peripheral blood progenitor cells in patients with h…

2001

BACKGROUND: The transplantation of autologous peripheral blood progenitor cells (PBPCs) after high-dose chemotherapy is a valuable therapy for patients with hematologic and solid malignancies. Several methods are used for harvesting PBPCs. The efficiency of intermittent- and continuous-flow blood cell separators in collecting progenitor cells from the blood of patients undergoing myeloablative treatment for cancer was compared. STUDY DESIGN AND METHODS: PBPC components (n = 133) were obtained from 72 patients by leukapheresis with continuous-flow machines (Spectra, COBE; CS 3000 Plus, Baxter) and with an intermittent-flow machine (MCS 3P, Haemonetics). The data were analyzed retrospectively…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentImmunologyUrologyCD34Blood volumeAntigens CD34Cell SeparationTransplantation AutologousBlood cellmedicineImmunology and AllergyHumansPlateletLeukapheresisProgenitor cellRetrospective StudiesChemotherapybusiness.industryHematopoietic Stem Cell TransplantationHematologyLeukapheresisMiddle AgedHematopoietic Stem CellsSurgeryBlood Cell CountTransplantationmedicine.anatomical_structureHematologic NeoplasmsFemalebusinessTransfusion
researchProduct

The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies.

1999

The etiology and pathogenesis of complex focal lesions associated with chronic, intractable epilepsy are largely unknown. Some data indicate that malformative changes of the central nervous system may preceed the development of gangliogliomas and other epilepsy-associated neoplasms. In the present immunhistochemical study, we have examined epilepsy-associated lesions for CD34, a stem cell marker transiently expressed during early neurulation. Surprisingly, most tissue samples from patients with chronic epilepsy (n = 262) revealed neural cells immunoreactive for CD34. Prominent immunoreactivity was detected in gangliogliomas (74%), low-grade astrocytomas (62%) and oligodendrogliomas (59%). O…

AdultPathologymedicine.medical_specialtyAdolescentImmunoblottingCD34Antigens CD34BiologyStem cell markerPathology and Forensic MedicineGangliogliomaPathogenesisCellular and Molecular NeuroscienceEpilepsyEpitopesmedicineHumansNeurogenesisHuman brainMiddle Agedmedicine.diseaseImmunohistochemistrymedicine.anatomical_structureChronic DiseaseImmunohistochemistryNeurology (clinical)Epilepsies PartialActa neuropathologica
researchProduct

Long-Term Human CD34+ Stem Cell-Engrafted Nonobese Diabetic/SCID/IL-2Rγnull Mice Show Impaired CD8+ T Cell Maintenance and a Functional Arrest of Imm…

2010

Abstract Allogeneic hematopoietic stem cell transplantation represents the most effective form of immunotherapy for chemorefractory diseases. However, animal models have been missing that allow evaluation of donor-patient–specific graft-versus-leukemia effects. Thus, we sought to establish a patient-tailored humanized mouse model that would result in long-term engraftment of various lymphocytic lineages and would serve as a donor-specific surrogate. Following transfer of donor-derived peripheral blood stem cells into NOD/SCID/IL-2Rγnull (NSG) mice with supplementation of human IL-7, we could demonstrate robust engraftment and multilineage differentiation comparable to earlier studies using …

AdultT cellTransplantation HeterologousImmunologyAntigens CD34Graft vs Leukemia EffectMice TransgenicMice SCIDCD8-Positive T-LymphocytesBiologyMiceInterleukin 21Immune systemMice Inbred NODmedicineAnimalsHumansImmunology and AllergyCytotoxic T cellCell LineageMice KnockoutMice Inbred BALB CCell DeathHematopoietic Stem Cell TransplantationCell DifferentiationKiller Cells NaturalMice Inbred C57BLmedicine.anatomical_structureCord bloodImmunologyHumanized mouseLymphocyte Culture Test MixedStem cellK562 CellsCD8Interleukin Receptor Common gamma SubunitThe Journal of Immunology
researchProduct

Rituximab in refractory pemphigus vulgaris

2008

Pemphigus vulgaris (PV) is a severe chronic autoimmune blistering disease of skin and mucous membranes. The use of systemic corticosteroids in pemphigus has dramatically reduced its mortality rate, but the long-term use of steroids leads to severe side effects, many of which are serious. For this reason it is often necessary to add immunosuppressive agents to the regimen. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects. Rituximab is a therapeutic monoclonal antibody targeting CD20, an integral membrane protein highly expressed on the surface of pre-B lymphocytes and a…

Adultmedicine.medical_specialtyAntigens CD19B-Lymphocyte SubsetsDrug ResistanceDermatologyDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRituximab pemphigus vulgarisimmune system diseasesHumansImmunologic FactorsMedicineInfusions IntravenousCD20integumentary systembiologybusiness.industryRemission InductionPemphigus vulgarisAntibodies MonoclonalGeneral MedicineAntigens CD20medicine.diseaseDermatologyRegimenPemphigusMonoclonalImmunologybiology.proteinPrednisoneDrug Therapy CombinationFemaleRituximabRituximabbusinessImmunosuppressive AgentsPemphigusmedicine.drugDermatologic Therapy
researchProduct

Analysis of T-Lymphocyte Subsets After Phytohemagglutinin Stimulation in Normal and Type 1 Diabetic Mothers and Their Infants

1992

Our aim was to investigate the immunological status of diabetic pregnancy, which is an overlap of diabetic immunity abnormalities and the immunological modifications normally occurring during pregnancy. METHOD: We studied lymphocyte subpopulations and lymphokine production, after 96 h of phytohemagglutinin (PHA) stimulation, from normal and Type I diabetic pregnant women at delivery time and from the respective cord blood. RESULTS: Peripheral blood mononuclear cells (PBMC) from both normal and Type I diabetic mothers showed an increase in CD8+ and a decrease in CD4+ cells compared to the respective cord blood mononuclear cells (CBMC). Moreover, Type I PBMC showed a lower number of “activate…

Adultmedicine.medical_specialtyCellular immunityCD3ImmunologyPregnancy in DiabeticsLymphocyte ActivationPeripheral blood mononuclear cellInterferon-gammaAntigens CDPregnancyT-Lymphocyte SubsetsInternal medicinemedicineHumansImmunology and AllergyIL-2 receptorPhytohemagglutininsCells CulturedImmunity CellularbiologyInterleukin-6Tumor Necrosis Factor-alphabusiness.industryLymphokineObstetrics and GynecologyReceptors Interleukin-2HLA-DR AntigensT lymphocyteFetal BloodFlow CytometryDiabetes Mellitus Type 1EndocrinologyReproductive MedicineCord bloodImmunologybiology.proteinInterleukin-2FemalebusinessCD8Interleukin-1American Journal of Reproductive Immunology
researchProduct

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Inn…

2007

To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day −1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follo…

Adultmedicine.medical_specialtyVincristineAntibodies NeoplasmImmunologyKaplan-Meier EstimateCHOPAntibodies Monoclonal HumanizedBiochemistryGastroenterologyChemoimmunotherapyAntigens CDAntigens NeoplasmMulticenter trialInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMulticenter Studies as TopicAlemtuzumabCyclophosphamideSocieties MedicalAgedGlycoproteinsDose-Response Relationship Drugbusiness.industryPralatrexateAntibodies MonoclonalLymphoma T-Cell PeripheralCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryRegimenCD52 AntigenItalyDoxorubicinVincristineAlemtuzumabPrednisonebusinessProgressive diseasemedicine.drug
researchProduct

Tif1γ regulates the TGF-β1 receptor and promotes physiological aging of hematopoietic stem cells.

2014

The hematopoietic system declines with age. Myeloid-biased differentiation and increased incidence of myeloid malignancies feature aging of hematopoietic stem cells (HSCs), but the mechanisms involved remain uncertain. Here, we report that 4-mo-old mice deleted for transcription intermediary factor 1γ (Tif1γ) in HSCs developed an accelerated aging phenotype. To reinforce this result, we also show that Tif1γ is down-regulated in HSCs during aging in 20-mo-old wild-type mice. We established that Tif1γ controls TGF-β1 receptor (Tgfbr1) turnover. Compared with young HSCs, Tif1γ(-/-) and old HSCs are more sensitive to TGF-β signaling. Importantly, we identified two populations of HSCs specifical…

AgingMyeloidReceptor Transforming Growth Factor-beta Type IReceptors Cell SurfaceCell SeparationBiologyProtein Serine-Threonine KinasesTransforming Growth Factor beta1MiceSignaling Lymphocytic Activation Molecule Family Member 1Antigens CDmedicineAnimalsMyeloid CellsRNA MessengerPolyubiquitinTranscription factorCellular SenescenceRegulation of gene expressionMultidisciplinaryUbiquitinationhemic and immune systemsBiological SciencesHematopoietic Stem CellsCell biologyHematopoiesisHaematopoiesismedicine.anatomical_structurePhysiological AgingPhenotypeGene Expression RegulationSignal transductionStem cellCell agingReceptors Transforming Growth Factor betaSignal TransductionTranscription FactorsProceedings of the National Academy of Sciences of the United States of America
researchProduct

Serum BPIFB4 levels classify health status in long-living individuals

2015

Background People that reach extreme ages (Long-Living Individuals, LLIs) are object of intense investigation for increase/decrease of genetic variant frequencies, genetic methylation levels, protein abundance in serum and tissues. The aim of these studies is the discovery of the mechanisms behind LLIs extreme longevity and the identification of markers of well-being. We have recently associated a BPIFB4 haplotype (LAV) with exceptional longevity under a homozygous genetic model, and identified that CD34+ of LLIs subjects express higher BPIFB4 transcript as compared to CD34+ of control population. It would be of interest to correlate serum BPIFB4 protein levels with exceptional longevity an…

AgingbiologyResearchmedia_common.quotation_subjectBPIFB4Disease progressionHaplotypeImmunologyBPIFB4; CD34; Methylation; Vascular ageingLongevityMethylationClinical nutritionVascular ageingMethylationAgeingImmunologyExtreme longevity trackingGenetic modelbiology.proteinCD34Antibodymedia_commonImmunity & Ageing
researchProduct